Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG

D. K. Perry, H. S. Pollinger, J. M. Burns, D. Rea, E. Ramos, J. L. Platt, J. M. Gloor, Mark D Stegall

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Donor-specific alloantibody presents a major barrier to the successful transplantation of kidneys and hearts. However, the study of alloantibody production has been hampered by both an inadequate source of antibody-secreting cells (ASCs) and a paucity of assays to determine their function. We describe two new assays that allow for the determination of the frequency and specificities of allo-ASCs in humans using purified HLA as targets. These assays demonstrated allo-ASCs in the CD138+ fraction of the bone marrow, but not in peripheral blood. Alloantibody specificities in these assays correlated well with those detected in the serum suggesting that bone marrow-derived ASCs are indeed a major source of alloantibody in vivo. However, ASCs for a specific HLA antigen were rare with an estimated frequency of only 1/2 × 106 marrow cells. Pretransplant treatment in vivo with multiple plasmaphereses and low-dose IVIG alone or in combination with rATG had no effect on ASC number or alloantibody production. These techniques allow for the study of allospecific ASCs and provide a method to test the potential efficacy of agents on alloantibody production in vivo.

Original languageEnglish (US)
Pages (from-to)133-143
Number of pages11
JournalAmerican Journal of Transplantation
Volume8
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Isoantibodies
Antibody-Producing Cells
Intravenous Immunoglobulins
Bone Marrow
Plasmapheresis
Heart Transplantation
HLA Antigens
Kidney Transplantation
Cell Count
Serum

Keywords

  • Alloantibody
  • HLA
  • Kidney transplant
  • Plasma cell
  • rATG

ASJC Scopus subject areas

  • Immunology

Cite this

Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. / Perry, D. K.; Pollinger, H. S.; Burns, J. M.; Rea, D.; Ramos, E.; Platt, J. L.; Gloor, J. M.; Stegall, Mark D.

In: American Journal of Transplantation, Vol. 8, No. 1, 01.2008, p. 133-143.

Research output: Contribution to journalArticle

Perry, D. K. ; Pollinger, H. S. ; Burns, J. M. ; Rea, D. ; Ramos, E. ; Platt, J. L. ; Gloor, J. M. ; Stegall, Mark D. / Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. In: American Journal of Transplantation. 2008 ; Vol. 8, No. 1. pp. 133-143.
@article{4a3557b4f3fe49eaa3930eb7d0f6b874,
title = "Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG",
abstract = "Donor-specific alloantibody presents a major barrier to the successful transplantation of kidneys and hearts. However, the study of alloantibody production has been hampered by both an inadequate source of antibody-secreting cells (ASCs) and a paucity of assays to determine their function. We describe two new assays that allow for the determination of the frequency and specificities of allo-ASCs in humans using purified HLA as targets. These assays demonstrated allo-ASCs in the CD138+ fraction of the bone marrow, but not in peripheral blood. Alloantibody specificities in these assays correlated well with those detected in the serum suggesting that bone marrow-derived ASCs are indeed a major source of alloantibody in vivo. However, ASCs for a specific HLA antigen were rare with an estimated frequency of only 1/2 × 106 marrow cells. Pretransplant treatment in vivo with multiple plasmaphereses and low-dose IVIG alone or in combination with rATG had no effect on ASC number or alloantibody production. These techniques allow for the study of allospecific ASCs and provide a method to test the potential efficacy of agents on alloantibody production in vivo.",
keywords = "Alloantibody, HLA, Kidney transplant, Plasma cell, rATG",
author = "Perry, {D. K.} and Pollinger, {H. S.} and Burns, {J. M.} and D. Rea and E. Ramos and Platt, {J. L.} and Gloor, {J. M.} and Stegall, {Mark D}",
year = "2008",
month = "1",
doi = "10.1111/j.1600-6143.2007.02039.x",
language = "English (US)",
volume = "8",
pages = "133--143",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG

AU - Perry, D. K.

AU - Pollinger, H. S.

AU - Burns, J. M.

AU - Rea, D.

AU - Ramos, E.

AU - Platt, J. L.

AU - Gloor, J. M.

AU - Stegall, Mark D

PY - 2008/1

Y1 - 2008/1

N2 - Donor-specific alloantibody presents a major barrier to the successful transplantation of kidneys and hearts. However, the study of alloantibody production has been hampered by both an inadequate source of antibody-secreting cells (ASCs) and a paucity of assays to determine their function. We describe two new assays that allow for the determination of the frequency and specificities of allo-ASCs in humans using purified HLA as targets. These assays demonstrated allo-ASCs in the CD138+ fraction of the bone marrow, but not in peripheral blood. Alloantibody specificities in these assays correlated well with those detected in the serum suggesting that bone marrow-derived ASCs are indeed a major source of alloantibody in vivo. However, ASCs for a specific HLA antigen were rare with an estimated frequency of only 1/2 × 106 marrow cells. Pretransplant treatment in vivo with multiple plasmaphereses and low-dose IVIG alone or in combination with rATG had no effect on ASC number or alloantibody production. These techniques allow for the study of allospecific ASCs and provide a method to test the potential efficacy of agents on alloantibody production in vivo.

AB - Donor-specific alloantibody presents a major barrier to the successful transplantation of kidneys and hearts. However, the study of alloantibody production has been hampered by both an inadequate source of antibody-secreting cells (ASCs) and a paucity of assays to determine their function. We describe two new assays that allow for the determination of the frequency and specificities of allo-ASCs in humans using purified HLA as targets. These assays demonstrated allo-ASCs in the CD138+ fraction of the bone marrow, but not in peripheral blood. Alloantibody specificities in these assays correlated well with those detected in the serum suggesting that bone marrow-derived ASCs are indeed a major source of alloantibody in vivo. However, ASCs for a specific HLA antigen were rare with an estimated frequency of only 1/2 × 106 marrow cells. Pretransplant treatment in vivo with multiple plasmaphereses and low-dose IVIG alone or in combination with rATG had no effect on ASC number or alloantibody production. These techniques allow for the study of allospecific ASCs and provide a method to test the potential efficacy of agents on alloantibody production in vivo.

KW - Alloantibody

KW - HLA

KW - Kidney transplant

KW - Plasma cell

KW - rATG

UR - http://www.scopus.com/inward/record.url?scp=37549061830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549061830&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2007.02039.x

DO - 10.1111/j.1600-6143.2007.02039.x

M3 - Article

C2 - 18184311

AN - SCOPUS:37549061830

VL - 8

SP - 133

EP - 143

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 1

ER -